A detailed history of Assenagon Asset Management S.A. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 2,144,415 shares of APLS stock, worth $71.2 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
2,144,415
Previous 734,708 191.87%
Holding current value
$71.2 Million
Previous $28.2 Million 119.44%
% of portfolio
0.13%
Previous 0.07%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$28.84 - $41.15 $40.7 Million - $58 Million
1,409,707 Added 191.87%
2,144,415 $61.8 Million
Q2 2024

Jul 18, 2024

SELL
$38.07 - $59.71 $49.1 Million - $77 Million
-1,288,906 Reduced 63.69%
734,708 $28.2 Million
Q1 2024

Apr 24, 2024

SELL
$55.39 - $72.47 $6.72 Million - $8.8 Million
-121,390 Reduced 5.66%
2,023,614 $119 Million
Q4 2023

Jan 17, 2024

BUY
$37.14 - $64.82 $41.7 Million - $72.7 Million
1,121,497 Added 109.57%
2,145,004 $128 Million
Q3 2023

Nov 06, 2023

BUY
$23.65 - $89.22 $12.4 Million - $46.8 Million
524,797 Added 105.23%
1,023,507 $38.9 Million
Q2 2023

Jul 25, 2023

SELL
$76.68 - $93.31 $18.8 Million - $22.8 Million
-244,536 Reduced 32.9%
498,710 $45.4 Million
Q1 2023

Apr 18, 2023

BUY
$46.59 - $66.96 $722,937 - $1.04 Million
15,517 Added 2.13%
743,246 $49 Million
Q4 2022

Jan 12, 2023

SELL
$43.24 - $61.04 $21.5 Million - $30.4 Million
-497,607 Reduced 40.61%
727,729 $37.6 Million
Q3 2022

Oct 27, 2022

BUY
$44.76 - $69.66 $15.3 Million - $23.8 Million
341,898 Added 38.7%
1,225,336 $83.7 Million
Q2 2022

Jul 27, 2022

BUY
$35.07 - $59.21 $13 Million - $21.9 Million
370,411 Added 72.2%
883,438 $39.9 Million
Q1 2022

Apr 25, 2022

BUY
$35.46 - $54.12 $15.8 Million - $24.1 Million
445,745 Added 662.5%
513,027 $26.1 Million
Q4 2021

Feb 01, 2022

BUY
$30.74 - $49.16 $2.07 Million - $3.31 Million
67,282 New
67,282 $3.18 Million
Q3 2021

Oct 19, 2021

SELL
$31.4 - $69.84 $7.4 Million - $16.5 Million
-235,775 Closed
0 $0
Q2 2021

Jul 15, 2021

BUY
$40.9 - $64.9 $9.64 Million - $15.3 Million
235,775 New
235,775 $14.9 Million
Q4 2020

Feb 01, 2021

SELL
$30.79 - $57.2 $505,972 - $939,967
-16,433 Closed
0 $0
Q3 2020

Oct 07, 2020

BUY
$25.89 - $33.65 $425,450 - $552,970
16,433 New
16,433 $496,000
Q4 2019

Jan 17, 2020

SELL
$22.1 - $30.8 $537,295 - $748,809
-24,312 Closed
0 $0
Q3 2019

Oct 16, 2019

BUY
$24.09 - $32.18 $585,676 - $782,360
24,312 New
24,312 $586,000
Q2 2019

Aug 12, 2019

SELL
$18.0 - $25.34 $5.56 Million - $7.83 Million
-308,992 Closed
0 $0
Q1 2019

Apr 26, 2019

BUY
$12.81 - $19.82 $3.96 Million - $6.12 Million
308,992 New
308,992 $6.03 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.65B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.